{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:49:16Z","timestamp":1777009756725,"version":"3.51.4"},"reference-count":47,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Comorbidities, common in patients with advanced breast cancer (ABC), may impact survival outcomes and health\u2010related quality of life (HRQoL). Here, we report subgroup analyses on the basis of comorbidities of patients from POLARIS (NCT03280303), a prospective, observational study of patients with hormone receptor\u2010positive\/human epidermal growth factor receptor 2\u2010negative (HR+\/HER2\u2212) ABC who were treated with palbociclib plus endocrine therapy in routine clinical practice in North America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Real\u2010world progression\u2010free survival (rwPFS) and overall survival (OS) were evaluated by line of therapy (1 LOT, \u2265\u20092\u2009LOT), Charlson Comorbidity Index (CCI) score (0, 1\u20132, and 3+), and common comorbid disorder categories (cardiovascular, psychiatric, metabolic and nutritional, and blood and lymphatic disorders). HRQoL was assessed using the global health status (GHS)\/QoL subscale of the European Organization for Research and Treatment of Cancer Quality\u2010of\u2010Life Questionnaire Core 30.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From January 2017 to October 2019, 1250 patients (median age, 64\u2009years) initiated palbociclib\u2010based therapy. Median rwPFS (95% CI) for patients with CCI scores of 0, 1\u20132, and 3+ were 20.3 (17.1\u201324.8), 24.2 (19.4\u201329.5), and 16.8 (11.2\u201320.8) months in 1 LOT and 13.7 (6.2\u201319.7), 13.2 (9.4\u201317.5), and 14.9 (8.0\u201321.9) months in \u2265\u20092\u2009LOT, respectively. Median OS durations (95% CI) were 48.8 (37.3\u2013not estimable [NE]), not reached (43.0\u2013NE), and 34.8 (29.1\u201344.1) months in 1 LOT and 39.0 (30.6\u201350.5), 37.9 (26.5\u201342.6), and 31.6 (20.9\u201345.2) months in \u2265\u20092\u2009LOT, respectively. Patients with blood and lymphatic disorders had shorter rwPFS and OS than those with other common comorbidities. GHS\/QoL was maintained irrespective of CCI score. Patients with a CCI score of 0 had clinically meaningful and statistically significantly higher mean GHS\/QoL scores than patients with a CCI score of 3+ at each assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with HR+\/HER2\u2212 ABC receiving palbociclib with higher comorbidity burden, especially blood and lymphatic system disorders, had poorer clinical outcomes. GHS\/QoL was preserved regardless of comorbidity burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Clinical trial number: NCT03280303<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71788","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:51:19Z","timestamp":1776865879000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor\u2010Positive\/Human Epidermal Growth Factor Receptor 2\u2010Negative (\n                    <scp>HR<\/scp>\n                    +\/\n                    <scp>HER2<\/scp>\n                    \u2212) Advanced Breast Cancer Treated With Palbociclib in the\n                    <scp>POLARIS<\/scp>\n                    Study"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-2404","authenticated-orcid":false,"given":"Debu","family":"Tripathy","sequence":"first","affiliation":[{"name":"Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne L.","family":"Blum","sequence":"additional","affiliation":[{"name":"Department of Oncology, Baylor\u2010Sammons Cancer Center Texas Oncology, US Oncology  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8795-3901","authenticated-orcid":false,"given":"Meghan S.","family":"Karuturi","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"McCune","sequence":"additional","affiliation":[{"name":"William S. Gibbons Cancer Research Institute Northwest Georgia Oncology Centers Wellstar  Marietta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sobha","family":"Kurian","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology West Virginia University Cancer Institute  Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi M.","family":"Moezi","sequence":"additional","affiliation":[{"name":"Medical Oncology Cancer Specialists of North Florida  Fleming Island Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Oncology &amp; Hematology Health Partners Institute  Saint Paul Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ji","sequence":"additional","affiliation":[{"name":"Health Partners Institute  St. Paul Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Pluard","sequence":"additional","affiliation":[{"name":"Saint Luke's Cancer Institute  Kansas City Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Migas","sequence":"additional","affiliation":[{"name":"Mid\u2010Illinois Hematology &amp; Oncology Associates Ltd  Normal Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailendra","family":"Lakhanpal","sequence":"additional","affiliation":[{"name":"Saint Vincent's Birmingham  Birmingham Alabama USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Jepsen","sequence":"additional","affiliation":[{"name":"Novant Health  Winston\u2010Salem North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[{"name":"Oncology Medical Group Pfizer Inc  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica Z.","family":"Montelongo","sequence":"additional","affiliation":[{"name":"Biostatistics and Medical Writing, ICON Commercialisation and Outcomes, ICON Plc.  Blue Bell Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Oncology Clinical Statistics Pfizer Inc  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Statistical Research and Data Science Center Pfizer Inc  Groton Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Pfizer Inc  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-9785","authenticated-orcid":false,"given":"Gabrielle B.","family":"Rocque","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.2196\/26425"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2017.05.010"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.20.2441"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.7.885"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010024\u201047002\u20103"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21342"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256536"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201015\u20101185"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy192"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/op.21.00384"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(15)00613\u20100"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(18)30292\u20104"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.10.005"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010019\u20100167\u20107"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020143"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523\u2010022\u201000479\u2010x"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102020\u20100573"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae291"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_13_26_1","volume-title":"Quality of Life: The Assessment, Analysis and Reporting of Patient\u2010Reported Outcomes, 2016","author":"Fayers P. M.","year":"2016"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.08.024"},{"key":"e_1_2_13_28_1","unstructured":"U.S. Food and Drug Administration Ibrance (palbociclib) \u2010 highlights of prescribing informationaccessed at June 6 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/207103s017s018lbl.pdf."},{"key":"e_1_2_13_29_1","volume-title":"Fundamentals of Biostatistics. 8th ed. 2015","author":"Rosner B.","year":"2016"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197\u20102456(96)00075\u2010x"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021\u20109681(87)90171\u20108"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.024"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi161"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b23\u201000187"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.07.017"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549\u2010024\u201007524\u20102"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw139"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy012"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34748"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100691"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211050106"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019\u20100019"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8994954"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00137"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810527"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058\u2010021\u201001409\u20108"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33959"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71788","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:08:29Z","timestamp":1777007309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/cam4.71788"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71788","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71788"}}